Evaluating gene expression patterns in myeloproliferative neoplasms
Expression Pattern of Heterogeneous Nuclear Ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) Genes in Myeloproliferative Neoplasms
This study is trying to see how certain genes behave in people who have just been diagnosed with myeloproliferative neoplasms to find clues about the disease and possible new treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 52 (estimated) |
| Sex | All |
| Sponsor | Assiut University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Assiut) |
| Trial ID | NCT05782985 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the expression patterns of the HNRNPH1 and HNRNPK genes in patients newly diagnosed with myeloproliferative neoplasms (MPNs). By utilizing reverse transcription-quantitative polymerase chain reaction (RT-qPCR), the study seeks to identify potential indicators of disease progression and therapeutic targets. The research focuses on understanding how these genes may influence the development of various forms of MPNs, including chronic myeloid leukaemia and polycythaemia vera. The findings could provide insights into the role of hnRNPs in hematologic malignancies.
Who should consider this trial
Good fit: Ideal candidates include individuals newly diagnosed with myeloproliferative neoplasms according to WHO criteria, regardless of age or gender.
Not a fit: Patients with other malignancies, those undergoing chemotherapy or radiotherapy, and individuals with autoimmune diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of MPNs and the development of targeted therapies.
How similar studies have performed: While the specific approach of evaluating HNRNPH1 and HNRNPK gene expression in MPNs may be novel, similar studies have shown that hnRNPs play a significant role in cancer progression.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: The study will be carried out on patients newly diagnosed with one of the myeloproliferative neoplasms based on WHO Criteria for diagnosis of MPNs whether males or females and of any age. Exclusion Criteria: * Other malignancies. * Patients on chemotherapy or radiotherapy. * Autoimmune diseases.
Where this trial is running
Assiut
- Assiut University Department of Clinical Pathology — Assiut, Egypt (Recruiting)
Study contacts
- Principal investigator: Alaa Elminshawy, MD, Mac — Assiut University
- Study coordinator: Alaa Elminshawy, MD, MSc
- Email: alaa.elminshawy@med.aun.edu.eg
- Phone: 01128892117
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.